A Gut Bacterium Triples Pneumonia Deaths in Mice, a Fatty Acid Reverses It

If you've ever wondered whether an infection somewhere else in the body could be quietly shaped by what's happening in the gut, a new study out of Dalian Medical University in China gives one of the clearest answers yet. Mice carrying a common food-borne gut microbe, one that caused zero digestive symptoms, went on to die from a drug-resistant lung infection three times more often than mice without it. In hospitalized pneumonia patients, the same microbe's level in stool tracked closely with how sick they were. The culprit wasn't the bacterium attacking the lungs directly. It was what its presence did to a single gut-derived fatty acid.

Key takeaways

• Mice silently colonized by Escherichia fergusonii died from carbapenem-resistant Klebsiella pneumoniae (CRKP) lung infection at 50%, versus 16.7% in uncolonized mice.
• The likely mechanism: colonization collapsed gut and lung levels of acetate, a short-chain fatty acid that normally helps keep lung immune cells in balance.
• In 54 hospitalized pneumonia patients, fecal levels of this bacterium correlated with illness severity (r = 0.808).
• Fecal transplant, oral acetate, and a probiotic reversed the damage in mice, but none of this has been tested as prevention in people. Do not read this as supplement advice.

Silent E. Fergusonii Gut Colonization Triples Pneumonia Deaths in Mice

Mice that carried Escherichia fergusonii (a food-borne bacterium that is the closest known relative of E. coli) in their gut, with no signs of illness at all, died from a drug-resistant lung infection at roughly three times the rate of mice that didn't carry it. The findings come from a study published August 18, 2026 in Communications Biology, a Nature Portfolio journal.

Researchers gave mice a course of the antibiotic clindamycin, then dosed them with E. fergusonii. The bacterium settled in and stayed for 21 days, confirmed by lab cultures and genetic testing, without causing any diarrhea, weight loss, or intestinal inflammation on tissue exams. It was colonization, not infection, in the ordinary sense. Twenty-one days in, the mice were exposed through the nose to carbapenem-resistant Klebsiella pneumoniae (CRKP), a strain of a common pneumonia-causing bacterium that has become resistant to carbapenems, one of the last-resort classes of antibiotics doctors reach for when other drugs fail. Mice that had been silently colonized developed worse lung damage (p < 0.0001), higher bacterial counts in their lungs (p < 0.0001), and died at 50%, compared with 16.7% in mice that had never carried the bacterium (p = 0.0014).

Why Carbapenem-Resistant Klebsiella Pneumonia Matters for High-Risk Patients

Carbapenem-resistant infections are already one of the deadliest problems in modern hospital medicine, and this finding suggests gut microbiome status could be a hidden factor in how badly they turn out. Carbapenem-resistant Enterobacterales, the broader bacterial family that includes CRKP, are formally classified by the CDC as an urgent public health threat, and in a recent year caused an estimated 1,100 deaths among about 13,100 hospitalized US patients, according to the CDC's antibiotic resistance threats tracking. CRKP disproportionately strikes people who are already vulnerable: ICU patients, people on ventilators, and anyone who has recently had heavy antibiotic exposure, which is exactly the situation in which gut dysbiosis (an imbalance in the normal mix of gut bacteria) is common. The human portion of this new study focused on that same population, hospitalized patients with confirmed K. pneumoniae pneumonia, and it points toward gut health as a possible amplifier of risk that has nothing to do with the lungs themselves.

How Researchers Tested the Gut-Lung Link, in Mice and in Patients

The study combined a controlled mouse model with an observational human cohort. In mice, researchers used groups of 6 animals each, tracked gut bacterial composition with genetic sequencing, measured short-chain fatty acids with mass spectrometry, and profiled immune cells in the lungs and spleen with flow cytometry. They also ran a fecal microbiota transplant (FMT) arm, restoring a more normal gut community to colonized mice before infecting them with CRKP, which partially reversed the worse outcomes.

The human arm was run at the Second Affiliated Hospital of Dalian Medical University between April and June 2024. Researchers measured E. fergusonii levels in stool from 25 healthy volunteers and 54 hospitalized patients with confirmed K. pneumoniae pneumonia, split into 30 who were critically ill and 24 who were not. Using a genetic quantification method, they found E. fergusonii was significantly higher in critically ill patients than in either the non-critically ill patients or the healthy controls (both p < 0.0001), and its abundance tracked closely with a standard clinical severity score, an adjusted correlation of r = 0.808 (p < 0.001).

What This Means If You're Managing Gut Health or Recurring Infections

This is not a reason to run out and buy an acetate supplement or a specific probiotic to protect against pneumonia. The protective results in this study, fecal transplant, oral acetate in drinking water, and a preliminary test of the probiotic strain Bifidobacterium animalis subsp. lactis BB-12, were all tested only in mice that were already colonized and then infected with drug-resistant bacteria. The study's own authors write that "the translational potential and therapeutic value of acetate in humans remain to be further validated." BB-12 does have a separate body of research suggesting it can support gut microbiota stability and respiratory immune function in other contexts, but that is not the same as this study's specific rescue effect, which remains an early, unreplicated finding in mice.

What is worth taking to a conversation with a doctor: if you or someone you're caring for has had repeated antibiotic courses, ongoing GI symptoms, or a history of severe or recurring respiratory infections, this study adds to a growing case that gut microbiome disruption is worth mentioning as part of the picture, particularly around hospital stays where antibiotic-driven dysbiosis is common before pneumonia even develops. It is not a diagnosis, and it is not a reason to self-treat.

The Study's Caveats: Small Mouse Groups and Cross-Sectional Human Data

Several limits matter here. The mouse groups were small, just 6 animals each, and an earlier survival experiment in the same paper, comparing untreated mice, FMT-treated mice, and mice with broadly depleted gut bacteria, showed mortality of 16%, 33%, and 50% that did not reach statistical significance (p = 0.238), which the authors attribute to that small sample size. It's the later, more targeted colonization experiment, with a clear comparison group and a larger effect (50% versus 16.7%, p = 0.0014), that produced the study's strongest and statistically solid result, and it's worth keeping those two experiments distinct.

The human data are cross-sectional, meaning everyone was sampled at a single point in time rather than followed over time, with 25 healthy controls and 54 patients. The authors themselves caution this design "may have introduced potential confounding variables and affected the generalizability" of their findings, and call for a larger, longitudinal study. The acetate differences that looked stark early in the mouse experiments also faded with time: by day 21, the drop in acetate had lost statistical significance in both the gut (p = 0.070) and the lungs (p = 0.159). For what it's worth, the authors reported no competing financial interests, and the work was funded entirely by public provincial education grants in China, with no company or commercial product tied to the specific bacterium or intervention studied. The manuscript is also still an unedited, publisher-flagged advance version, meaning some details could shift before final publication.

What Comes Next for Acetate as a Potential Intervention

The researchers are explicit that this is a mechanistic starting point, not a finished therapy. They're calling for a larger, longitudinal human study to test whether gut E. fergusonii levels or acetate actually predict how a patient's pneumonia will progress over time, rather than just correlating with severity at a single snapshot. They also flag that human validation of whether restoring acetate levels changes real-world outcomes hasn't been done, and that broader metabolic profiling beyond acetate alone is needed, since short-chain fatty acids as a class are already known to shape lung immune tone through several overlapping pathways that this study didn't fully map.

Common Questions

What is Escherichia fergusonii, and is it dangerous on its own? It's a food-borne bacterium closely related to E. coli that can colonize the gut without causing any symptoms. In this study, colonized mice showed no signs of infection or intestinal damage, but that silent presence still reshaped their immune defenses against a separate, unrelated lung infection.

Should I take a probiotic or acetate supplement to protect against pneumonia? No. The protective results, fecal transplant, oral acetate, and a Bifidobacterium BB-12 probiotic, were tested only in mice already colonized and infected with drug-resistant bacteria, not as a human prevention strategy, and the study's authors explicitly say acetate's therapeutic potential in people still needs to be validated.

Was this tested in people at all? Yes, but only observationally. Researchers measured E. fergusonii levels in stool from 54 hospitalized K. pneumoniae pneumonia patients and 25 healthy volunteers and found the bacterium's abundance closely tracked with how sick patients were, though a cross-sectional design like this one can't prove the bacterium caused the worse outcomes.

References

1. Yuyuan Li, Jing Yu, Qi Li, et al. (2026). Gut microbiota-derived acetate mitigates Escherichia fergusonii-induced gut dysbiosis exacerbating Klebsiella pneumoniae pulmonary infection in mice. Communications Biology. https://doi.org/10.1038/s42003-026-10793-w
2. Carbapenem-resistant Enterobacterales (CRE): An urgent public health threat. arpsp.cdc.gov. https://arpsp.cdc.gov/story/cre-urgent-public-health-threat
3. Antibiotic Resistance Threats in the United States, 2019 (CDC). cdc.gov. https://www.cdc.gov/antimicrobial-resistance/media/pdfs/2019-ar-threats-report-508.pdf
4. Mikkel Jungersen, Anette Wind, Eric Johansen, Jeffrey Christensen, Birgitte Stuer-Lauridsen, Dorte Eskesen (2014). The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12®. Microorganisms. https://doi.org/10.3390/microorganisms2020092
5. Sumel Ashique, Gabriele De Rubis, Ekta Sirohi, et al. (2022). Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases. Chemico-Biological Interactions. https://doi.org/10.1016/j.cbi.2022.110231